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In the present study, we demonstrate for the first time the presence of a specific receptor for protein HC on the surface 
of human cells using the human histiocytic lymphoma cell line U937. Cells treated for 4 days with the maturation inducer 
phorbol 12-myristate 13-acetate, were found to increase both the number of cells binding protein HC (76% higher than 
for untreated cells) and the expression of protein HC receptors. Protein HC bound to these cells in a specific and saturable 
manner. Scatchard analysis at 4°C using radioiodinated protein HC, indicated a single class of low-affinity receptor 
(K,= 225 x 10’ M-i) and 20000-30000 receptors per cell. Monoclonal antibodies against protein HC abrogated specific 
binding of this protein to U937. In contrast, monoclonal antibodies that did not react with protein HC (anti-LFA-la, 
anti-MOla) were without effect on the binding reaction. 
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1. INTRODUCTION 
Protein HC, also called ai-microglobulin, is a 
181-amino acid single-chain glycoprotein original- 
ly isolated from normal human urine [1,2]. The 
protein is associated with a brown chromophore 
and is present in different human body fluids both 
free and complexed to IgA [3-61. This complex is 
composed of protein HC covalently linked to the 
Fc fragment of IgA in a 1: 1 stoichiometric ratio 
[7]. Although protein HC was recently shown to be 
synthesized by hepatoma cell lines and isolated 
hepatocytes of human liver [8], there is still con- 
troversy concerning its tissue origin [9,10]. 
Several attempts have been made to define the 
biological role of protein HC and recently it has 
been described to inhibit the chemotactic response 
of neutrophils to endotoxin-activated serum [ 1 l] 
and to exert mitogenic effects on lymphocytes in 
the presence of accessory cells [ 121. 
These observations prompted us to study the 
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biochemical basis for protein HC-dependent 
cellular responses. Using radioiodinated protein 
HC we have established the presence of specific 
protein HC receptors in the human monocytic cell 
line U937. 
2. MATERIALS AND METHODS 
2.1. Radioactive ligand 
Purified protein HC was generously provided by Dr A. 
Grubb of Lund University (Lund, Sweden). ‘251-labeled protein 
HC (“‘1-HC) was prepared by the chloramine-T method [13]. 
Protein-associated and free ‘a51 were separated by centrifuga- 
tion through tubes containing Sephadex G-25 as described by 
Fishelson et al. [14]. Typical preparations were labeled to a 
specific activity of 3.8 ,Ki/pg. 
2.2. Fluoresceinated ligand 
Fluorescein isothiocyanate (FITC) labeling of protein HC 
(FITC-HC) was accomplished by incubation of 1 mg/ml pro- 
tein with 2 mM FITC (Molecular Probes Inc., Plano, TX) in 
10 mM borate buffer, pH 9.7, for 2 h at 4°C. Bound and free 
FITC were separated by gel filtration on a 10 ml Sephadex G-25 
column. Protein concentration was determined by the method 
of Lowry et al. [15]. 
2.3. Monoclonal antibodies 
Monoclonal antibody to protein HC was obtained from Dr 
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A. Grubb (Lund University, Lund, Sweden). Monoclonal anti- 
bodies to LFA-lcu and MOla were generous gifts from Dr F. 
Sanchez-Madrid (Hospital de la Princesa, Madrid, Spain) and 
Dr J.E. De Vries (The Netherlands Cancer Institute, Amster- 
dam, The Netherlands), respectively. 
2.4. Cell culture 
The human histiocytic lymphoma cell line U937 was main- 
tained in culture in RPMI-1640 (Flow laboratories, Inglewood, 
CA) supplemented with 10% heat-inactivated fetal calf serum 
(Gibco, Uxbridge, England), 2% L-glutamine, 1% sodium 
pyruvate (both from M.A. Bioproducts, Walkersville, MD), 
50 U/ml penicillin and 50pg/ml streptomycin (both from Eli 
Lilly and Co., Indianapolis, IN). Cells were incubated with 
phorbol 12-myristate I3-acetate (Sigma Chemical Co., St. 
Louis, MO) to a final concentration of 35 ng/ml for 1 to 4 days 
and the adherent population was analyzed for HC binding 
capacity. 
2.5. Binding assays 
Two million U937 cells were incubated with different concen- 
trations of ‘*‘I-HC in a total volume of 200~1 with RPMI- 
supplemented medium. After 2 h at 4”C, 180 pl was applied to 
250 pl of an oil mixture consisting of six parts dioctylphthalate 
and four parts dibutylphthalate (Eastman Kodak Co., 
Rochester, NY) in 40081 polyethylene microfuge tubes (Bio- 
Rad Lab., Richmond, CA) and microfuged at 4°C for 1 min in 
a Beckman microfuge B. Tubes were sectioned and the radioac- 
tivity of the pellet and supernatant counted. Specific binding 
was defined as the difference between total binding and the 
nonspecific binding occurring in the presence of a IOOO-fold ex- 
cess of unlabeled protein HC. 
2.6. Flow cytometry analysis 
Fluorescence analysis was performed with an EPICS-C cyto- 
fluorometer (Coulter Cientifica, Mostoles, Spain). Briefly, 
400000 cells were incubated with I pg FITC-HC for 80 min at 
4°C. After three washes with cold PBS containing 1% BSA and 
10 mM sodium azide, the cells were resuspended in 500 pl of the 
same buffer and analyzed by flow microfluorometry. Back- 
ground fluorescence was determined by incubating cells with 
FITC-conjugated F(ab’)z goat anti-human Ig (Behring Werke, 
Marburg, FRG). Data were displayed as profile histograms 
plotting fluorescence intensity vs cell number. 
3. RESULTS 
3.1. Induction of protein HC receptor expression 
by PMA 
The ability to induce U937 maturation in vitro 
provided a mechanism to study the expression of 
the protein HC receptor at different stages of dif- 
ferentiation. In all experiments, differentiation 
was confirmed morphologically by light micro- 
scopy and by conversion of the cells to an adherent 
population. U937 cells were found to increase the 
expression of protein HC receptor after phorbol 
12-myristate 13-acetate (PMA) treatment as shown 
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by flow cytometry analysis (fig.1, right panel). 
Before incubation with PMA, 10.38% of the U937 
cells expressed protein HC receptors. After one 
day induction with PMA, 35.50% of the adherent 
population expressed the receptor, without signifi- 
cant variation of fluorescence intensity. In- 
terestingly, four day incubation with PMA 
increased both the percentage of cells binding pro- 
tein HC (87.13%) and the fluorescence intensity of 
these cells. Background was determined by incuba- 
tion of cells with FITC-conjugated F(ab ‘)z 
fragments of goat anti-human Ig (fig. 1, left panel). 
In all cases, less than 6% of the cells were 
positives. 
3.2. Characteristics of protein HC binding 
The protein HC receptor of U937 cells after dif- 
ferentiation by four day culture with PMA, was 
defined in ligand binding experiments. These 
studies used radioiodinated protein HC which re- 
tained the antigenic reactivity with monoclonal 
anti-protein HC. 
Fig.2. shows that 1251-HC binds to U937 cells in 
a specific and saturable manner at 4°C. In these 
experiments, more than 90% of the total binding 
was specific, since it was blocked in the presence of 
a lOOO-fold excess of unlabeled protein HC. The 
cell population exhibited a single class of low- 
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Fig.1. Induction of protein HC receptor expression by PMA. 
U937 cells were incubated with 36 ng/ml of PMA and the ex- 
pression of protein HC receptor assessed by incubation with 
fluoresceinated protein HC (right). Background was established 
by incubating cells with FITC-F(ab’)z goat anti-human Ig (left). 
Untreated U937 cells represented the negative control in this 
assay. Numbers indicate the percentage of positive cells. 
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Fig.2. Quantitation of protein HC binding to U937. Cells were 
incubated at 4°C for 2 h with different amounts of ‘*‘I-HC. 
The inset represents Scatchard analysis of the data. B, bound 
protein HC; F, free protein HC. 
affinity binding sites, K, = 2-5 x 10’ M-‘. The 
number of binding sites per cell ranged from 20 000 
to 30000 for r2’I-HC. 
3.3. Specificity of protein HC binding 
As shown in fig.3, incubation of U937 cells with 
‘251-HC in the presence of monoclonal antibodies 
against protein HC resulted in inhibition of more 
than 90% of the “‘1-HC binding to these cells (in- 
puts of 100 ng “‘1-HC). On the other hand, mono- 
clonal antibodies that did not react with protein 
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Fig.3. Specificity experiments for “‘1-HC binding to U937 
Cells were incubated for 2 hat 4°C with “‘1-HC (100 ng) in the 
presence of different monoclonal antibodies. Binding assay was 
carried out as described in section 2. 
HC (anti-LFA-lcz, anti-MOla) displayed no in- 
hibitory activity on the binding reaction. 
4. DISCUSSION 
The data presented in this report establish the 
presence of specific protein HC receptors on the 
human histiocytic lymphoma cell line U937. Ex- 
pression of protein HC receptors were shown to be 
influenced by cellular differentiation. After four 
day culture with PMA, the number of mature 
(adherent) U937 cells expressing the receptor was 
76% higher than for untreated (non-adherent) cells 
(fig.1). In addition, these cells were found to in- 
crease the expression of protein HC receptor as 
shown by flow cytometry. 
Binding of radioiodinated protein HC to mature 
U937 cells (PMA-treated for 4 days) at 4°C was 
noncooperative and saturable. These cells express- 
ed 20 000-30000 receptors/cell and bound ligand 
with low affinity (Ka = 2-5 x 10’ M-l). The inter- 
action was specific because uptake of radiolabeled 
ligand was inhibited only by unlabeled protein HC 
or by monoclonal anti-protein HC. 
According to these results, protein HC receptor 
could be a component of the mature mononuclear 
phagocyte plasma membrane. This would relate 
the behaviour of the protein HC receptor to that of 
the Fc and C3b receptors, which are used as mono- 
cyte/macrophage differentiation markers, since 
they are expressed only on differentiated forms of 
mononuclear phagocytes [ 16,171. 
Protein HC has been shown to induce lympho- 
cyte proliferation in the presence of accessory cells 
[ 121. On the basis of the studies presented here, 
protein HC could mediate lymphocyte activation 
through binding to specific receptors on mono- 
nuclear phagocytes. This interaction could induce 
the secretion of a second signal which would lead 
lymphocytes to proliferate. Protein HC did not in- 
duce the secretion of IL-1 when it was incubated 
with different monocytic cell lines (not shown). 
Thus, another mediator must be responsible for 
the postulated mechanism of lymphocyte ac- 
tivation. 
It will be of interest to demonstrate the presence 
of protein HC receptors on other cells e.g. 
peripheral blood monocytes, macrophages, 
neutrophils, and to elucidate if there is a single 
type of protein HC receptor. 
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The identification of a protein HC receptor on 
U937 cells represents the first step toward under- 
standing the mechanism of action of protein HC. 
Work is currently in progress to characterize the 
receptor and to determine its fate after receptor- 
ligand interaction. 
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